AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Given the volatility of AbbVie's (NYSE: ABBV) stock over the past year, it's pretty clear that traders are worried about next year's impending Humira patent cliff. Although the way AbbVie is going, an earnings slump is likely to be short-lived. Humira was seen as a blockbuster from the beginning; the rheumatoid arthritis medication brought in $800 million in its first full year of sales in 2003, back when AbbVie was still part of Abbott Laboratories.
The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.